Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584521 | 1.00 | ADRB3 (0.55) | ADRB3ADRB1ADRB2KCNA5CYP1A2 | |
| SCHEMBL27668001 | 1.00 | ADRB3 (0.55) | ADRB3ADRB1ADRB2KCNA5CYP1A2 | |
| SCHEMBL4584631 | 0.88 | ADRB1 (0.54) | ADRB3ADRB1ADRB2KCNA5 | |
| SCHEMBL4584636 | 0.88 | ADRB1 (0.54) | ADRB3ADRB1ADRB2KCNA5 | |
| SCHEMBL5703832 | 0.83 | ADRB3 (0.52) | ADRB3ADRB1ADRB2SMN1; SMN2 | |
| SCHEMBL5703841 | 0.81 | CHRNA7 (0.57) | ADRB3ADRB1ADRB2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4582623 | 0.79 | ADRB3 (0.73) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4585340 | 0.78 | ADRB3 (0.66) | ADRB3ADRB1ADRB2 | |
| SCHEMBL27647623 | 0.78 | ADRB3 (0.66) | ADRB3ADRB1ADRB2 | |
| SCHEMBL8559634 | 0.76 | ADRB3 (0.54) | ADRB3ADRB1ADRB2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB3 86/4885ADRB1 70/4885ADRB2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.